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Abstract
Background: This paper presents the model and results to evaluate the use of teriparatide as a first-line treatment
of severe postmenopausal osteoporosis (PMO) and Glucocorticoid-induced osteoporosis (GIOP). The study’s
objective was to determine if teriparatide is cost effective against oral bisphosphonates for two large and high risk
cohorts.
Methods: A computer simulation model was created to model treatment, osteoporosis related fractures, and the
remaining life of PMO and GIOP patients. Natural mortality and additional mortality from osteoporosis related
fractures were included in the model. Costs for treatment with both teriparatide and oral bisphosphonates were
included. Drug efficacy was modeled as a reduction to the relative fracture risk for subsequent osteoporosis related
fractures. Patient health utilities associated with age, gender, and osteoporosis related fractures were included in
the model. Patient costs and utilities were summarized and incremental cost-effectiveness ratios (ICERs) for
teriparatide versus oral bisphosphonates and teriparatide versus no treatment were estimated.
For each of the PMO and GIOP populations, two cohorts differentiated by fracture history were simulated. The first
contained patients with both a historical vertebral fracture and an incident vertebral fracture. The second contained
patients with only an incident vertebral fracture. The PMO cohorts simulated had an initial Bone Mineral Density
(BMD) T-Score of −3.0. The GIOP cohorts simulated had an initial BMD T-Score of −2.5.
Results: The ICERs for teriparatide versus bisphosphonate use for the one and two fracture PMO cohorts were
€36,995 per QALY and €19,371 per QALY. The ICERs for teriparatide versus bisphosphonate use for the one and two
fracture GIOP cohorts were €20,826 per QALY and €15,155 per QALY, respectively.
Conclusions: The selection of teriparatide versus oral bisphosphonates as a first-line treatment for the high risk
PMO and GIOP cohorts evaluated is justified at a cost per QALY threshold of €50,000.
Keywords: Glucocorticoid-induced osteoporosis, Postmenopausal osteoporosis, Cost-effectiveness, Fractures,
Teriparatide, Bisphosphonate
Background
Osteoporosis is a common disease that is characterized by a
significant loss of bone mass. While some gradual loss of
bone mass occurs in most people as they age, those with
osteoporosis see an accelerated loss. The impact of this accel-
erated loss is a substantially higher risk of bone fractures.
Because osteoporosis has no symptoms, a diagnosis fre-
quently occurs only after a fracture event.
Osteoporosis related fractures have a significant impact
on quality of life, medical costs, and mortality. A 2007 study
by Borgström et al. [1] estimated the costs of osteoporosis
in Sweden at SEK 8.5 billion annually. Statistics from Kanis
et al. [2] indicate that the chance of an osteoporosis related
hip fracture in a 50 year old Swedish woman (in their
remaining lifetime) was 22.9%. Another analysis from Kanis
et al. [3] indicates that mortality risk after an osteoporosis* Correspondence: drm@mdm-inc.com†Equal contributors
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related hip fracture increases by 20 to 30 percent for three
to six months after the event solely due to the fracture.
Treatment for osteoporosis often follows diagnosis after a
fracture event, but may be initiated earlier if risk factors for
a diseased patient are identified. A bone mineral density
(BMD) test is the standard diagnostic tool to confirm the
condition. The test measures the density of minerals (such
as calcium) using dual energy X-ray absorptiometry (DXA)
or computed tomography (CT) scan. The test output is
called a T-score. A T-score is defined as the difference,
reported in units of standard deviation (SD), between the
individual’s measured BMD and that of a healthy young
adult. A test result indicating more than −2.5 SD from the
reference mean value is defined as clinical osteoporosis.
Among osteoporosis patients two disease subgroups
were identified for analysis within this study:
1. Postmenopausal osteoporosis (PMO) patients [4-7] –
Postmenopausal women represent the largest group
of osteoporosis patients.
2. Glucocorticoid-induced osteoporosis patients (GIOP)
[8] – GIOP is the most common cause of secondary
osteoporosis [9]. Glucocorticoids (e.g., prednisone) are
typically used to treat rheumatoid arthritis, lupus,
myositis, and polymyalgia rheumatica. GIOP patients
are at very high risk of fractures through the depletion
of bone mass [10,11].
First-line pharmaceutical treatment for both PMO and
GIOP patients typically involves one of several oral bispho-
sphonates [12]. In normal adults, bone mass is continually
being created and reabsorbed by the body. Bisphosphonates
work by slowing the rate at which bone is reabsorbed. For
severe PMO and GIOP patients, however, slowing bone re-
absorption may not be sufficient in reducing the risks of
osteoporosis related fractures. Unlike bisphosphonates, teri-
paratide acts by stimulating osteoblasts, increasing the
number and function of osteoblasts and leading to new
bone formation. When bisphosphonates are insufficient,
the use of teriparatide may be indicated.
Past studies have indicated that teriparatide is more clin-
ically efficacious than bisphosphonates for PMO and GIOP
patients [8]. Bisphosphonates, however, represent a signifi-
cantly lower (direct) cost treatment option. This poses the
primary objective of this cost effectiveness analysis; to com-
pare teriparatide in first-line use against bisphosphonates
and against no treatment in two high risk cohorts. Our goal
in doing so was to evaluate under what conditions teripara-
tide may represent a cost effective first-line option.
Methods
Cost effectiveness model
The study used a java based microsimulation model to esti-
mate patient events, costs, utilities, and cost-effectiveness.
The model simulates the lives of patients from a given start-
ing age until death or until the end of follow-up. Hip frac-
tures, clinical vertebral fractures, and wrist fractures were
modeled. The modeled mortalities were population-based
natural mortality and excess mortality due to fracture. The
model has a cycle length of six months. During each cycle,
the simulated patients were at risk of both osteoporosis
related fractures and death.
The model is implemented as a Monte Carlo simula-
tion: a large number of individual patients are stochas-
tically processed through the model. Identical cohorts of
patients are simulated by the model to compare costs
and benefits for teriparatide treatment, bisphosphonate
treatment, and no treatment. The simulated patients are
defined by a set of initial characteristics. The primary
characteristics are the patient’s starting age, gender, and
initial BMD T-score. The base case analyses were per-
formed using 200 replications of 100,000 simulated
patients. Results are saved for each patient and the mean
expected cost and effectiveness for each cohort is calcu-
lated. The basic flow of patients within the model is
shown in Figure 1.
Costs estimated by the model included those asso-
ciated with treatment and with fracture events. Patient
utility values were also estimated by the model. These
were age-dependent values that were multiplied accord-
ingly by fracture site-specific utility multipliers, both in
the six month cycles in which the fractures occurred and
in subsequent cycles. Costs and utilities were reduced in
the six month cycles in which death occurred. Both costs
and benefits were discounted at annual discount rates of
3%. Model results were analysed by comparing the aver-
age cost and utility-determined quality-adjusted life year
(QALY) values for the three treatment options. The
model also estimated the cohort’s undiscounted life years
associated with each treatment option.
Patient cohorts
For the analysis of teriparatide treatment in PMO
patients, two patient cohorts were simulated:
 Patients with a BMD T-score of −3.0 SD below the
mean, a historical vertebral fracture (5 years
previous) and an incident vertebral fracture (6
months previous) using teriparatide as a first-line
treatment; and
 Patients with a BMD T-score of −3.0 SD below the
mean and an incident vertebral fracture using
teriparatide as a first-line treatment.
In both PMO cohorts females were evaluated with treat-
ment starting at age 69. The patient age, fracture history,
and BMD used for this analysis were selected to represent
the prime years of recognition and treatment for a severe
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PMO case requiring immediate and aggressive treatment.
The inclusion of both a historical and an incident verte-
bral fracture in the first patient cohort is reflective of reim-
bursement criteria for PMO patients in Sweden. Criteria
vary between countries, with many requiring three or
more previous fractures based on patient age and T-score.
For the analysis of teriparatide treatment in GIOP
patients, two cohorts were examined:
 Patients with GIOP, a BMD T-score of −2.5 SD
below the mean, a historical vertebral fracture (5
years previous) and an incident vertebral fracture
using teriparatide as a first-line treatment, and
 Patients with GIOP, a BMD T-score of −2.5 SD
below the mean, and an incident vertebral fracture
using teriparatide as a first-line treatment.
The GIOP cohorts evaluated also started as 69 year
old patients. They are a combination of males and
females that reflect the gender proportion of patients
with GIOP. The assumption of 80% female GIOP
patients was based on the participant characteristics of a
published clinical trial assessing the benefit of treatment
with teriparatide for patients with GIOP [8].
Model data sources
A summary of data sources used in the model is pre-
sented in Table 1. A detailed listing of model data and
references is provided in Additional file 1: Appendix A,
Table A1.
Fracture risks
Fracture risks in the model were based on age; gender;
mean and measured T-scores; the timing and type of
previous fractures; glucocorticoid use; and treatment.
The algorithm implemented for the calculation of frac-
ture risk is from a systematic review [13] addressing the
treatment of GIOP. Relative fracture risks were applied
to the baseline risks to compensate for the additional
risks associated with previous fractures and glucocortic-
oid use. Treatment-dependent relative risks (or therapy
fracture efficacy rates) were applied to obtain the frac-
ture risks with treatment. The treatment-dependent rela-
tive risks were applied during the course of treatment
and were phased out after the completion (or cessation)
of treatment.
First fracture risks for Swedish females with average
BMD values were adjusted for age. The ratios of UK
male to female fracture risks from Kanis (Table twenty)
[13] were applied to the Swedish female fracture risks to
impute the corresponding fracture risks for Swedish
males. The model assigns the fracture risks to the mid-
point of the stated age ranges, e.g., the 50–54 fracture
risk values were assigned to 52 year olds. Fracture risks
for other ages were interpolated from the table values.
Figure 1 Model Flow for Patient Treatment (Rx) and Fracture Generation (Fx).
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Baseline fracture risks for a given GIOP patient were cal-
culated by applying an additional relative risk factor [13].
The additional relative risk factor reflects the increased risk
of fracture due to prior or current glucocorticoid use.
Fracture risks were also dependent on previous frac-
tures [14]. The base model assumed that the relative risk
of fracture after a previous fracture was not age-
dependent. The base model also assumed that the im-
pact on fracture risk from a previous fracture continued
for a period of 5 years after each fracture. The model
has the capability to modify this post-fracture impact
timeframe, ranging from no post-fracture impact to pa-
tient lifetime post-fracture impact.
In the case of multiple historical fractures of different
types, the model utilizes the largest relative risk of frac-
ture multiplier. The model includes an additional risk
due to a second fracture of each type. This was set as an
additional percentage of the risk increase due to the first
fracture (50% increase for GIOP patients and 100% for
PMO patients).
Fracture costs
Costs of a fracture were divided into acute costs, which
occur during the first six-month cycle following the frac-
ture, and continuing long-term costs which are modeled as
persisting for the remainder of the patient lifetime. Where
data were available, costs were differentiated by age groups.
Fracture costs were summed for a model cycle. Cycle costs
for a given model cycle may include multiple acute six-
month costs for different fracture types, as well as multiple
continuing costs from previous fractures.
Acute fracture costs are accumulated during the first
six months after hip, clinical vertebral, and wrist frac-
tures. Continuing costs accrue in post-fracture cycles for
the lifetime of the patient. Wrist fractures are assumed
to result in no continuing costs. For hip fractures, con-
tinuing costs are based on the cost of nursing home care
and the likelihood that the fracture resulted in admit-
tance to a nursing home. Continuing costs for clinical
vertebral fractures include costs for each six months of
analgesic usage.
For a repeat occurrence of a fracture event with long-
term continuing costs, the model adds the acute six-
month costs of the fracture event, and then subsequently
uses only the continuing costs of the repeat fracture
(thus avoiding potential double-counting of long-term
care costs). This approach also allows for the higher
long-term continuing costs associated with older
patients to supersede lower long-term continuing costs
from previous fractures. In the rare cases where the pre-
vious fracture event’s long-term continuing costs are
higher, the higher costs are accumulated.
Drug intervention, physician, and testing costs
Patients were assumed to be treated either with teripara-
tide for 18 months, with bisphosphonates for 18 months,
Table 1 Key model parameters
Parameter Value References
Baseline Fracture Risks based on Fx type, age, and gender, BMD [2,13]
Fracture Relative Risks - GIOP by fracture type based on age [13]
Fracture after Fracture and Second Fracture Relative Risks based on fracture type and age [13,14]
Drug Costs Teriparatide- Avg. Daily Cost: €14.74 [15]
Alendronate – Avg. Daily Cost: €0.42
Acute and Long-Term Direct Fracture Costs by age and fracture type [14,28]
Currency SEK to € Conversion 9.0335 ; 12 month average ending December 2011 [16]
Continuing 6 Month Care Costs €201 (months 1–6,13-18) [17]
€194 (months 7–12)
Natural Mortality Swedish Life Tables based on age and gender;
adjusted to remove osteoporosis fracture deaths
[13,18]
Fracture Mortality based on age and gender; [13]
0.007 (65 year male) to 0.0375 (90+ year old female)
Relative Risk of Mortality Post Fracture For hip fractures and vertebral fractures; ranges:
2.5 (year 1) to 1.0 (year 7)
[19,20]
Base Health Utilities by age; from 0.84 (through age 50) to 0.65 (age 85) [21]
Fracture Utility Multipliers first year and subsequent years, by fracture type [13]
Teriparatide Anti-Fracture Efficacies Relative Risks by fracture type and treatment period [4-7]
Bisphosphonate Anti-Fracture Efficacies Relative Risks by fracture type and treatment period [13]
Teriparatide Discontinuation 3, 9, and 15 month values interpolated to 6 month cycles [22]
Bisphosphonate Discontinuation by 6 month cycle [23]
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or with no treatment. Drug costs came from the Swedish
Dental and Pharmaceutical Benefits Agency (TLV) his-
torical database on pricing decisions [15]. The daily cost
of teriparatide was set as €14.74, representing the public
price in Sweden of a teriparatide pen (28 injections for
3,728.50 SEK). The daily bisphosphonate intervention
cost was set as €0.42, based on the price for generic 10
mg daily alendronate (98 tablets for 372.00 SEK). Note
that a weekly dose of alendronate at a slightly higher
daily cost (based on the TLV database) is also available.
The lower cost option, least favourable to teriparatide,
was selected for this analysis.
Costs for physician visits and BMD testing were taken
from the Swedish 2011 Regional Rates and Allowances
for Southern Health Region price list [17]. For visits in-
volving a BMD test, the cost was set as the price for an
osteoporotic measurement visit (in Malmo) of 1,125
SEK plus the cost of a hand BMD measurement of 695
SEK. For visits not involving a BMD measurement, the
cost was set as the basic rate in Malmo for the most re-
cent doctor seen by the patient, 1,756 SEK. Patient visits
(and their costs) were assigned for every six-month cycle
that a simulated patient receives treatment. Over 18
months of teriparatide or bisphosphonate therapy, this
results in 3 visits for adherent patients. The cost for
BMD measurements was assigned to treated patients in
the first six-month cycle and subsequently every other
six-month cycle. The base case analysis has no side ef-
fect costs for treatment with teriparatide or
bisphosphonates.
Treatment discontinuation
The model estimates cycle-by-cycle treatment discon-
tinuation. For the base case analysis, teriparatide discon-
tinuation of treatment was based on European Forsteo
Observational Study (EFOS) data from Langdahl [22]
(Figure 1). The discontinuation of bisphosphonate treat-
ment was based on time to persistence failure data
reported by Weycker [23].
Mortality
The model simulates both natural (i.e., not fracture-
related) mortalities and fracture-related excess mortal-
ities. The age-gender-specific mortality rates for the
general population in Sweden were based on data from
the Swedish Life Tables for years 2003–2007 [18]. In
order to avoid the double-counting of fracture-related
excess mortalities, the proportions of deaths attribut-
able to fracture from Kanis [13] (Tables twenty seven
and twenty nine) were removed from the Swedish
mortality rates to obtain the natural mortality rates
without fractures. For the accumulation of treatment
intervention costs, fracture event costs, and health
state utilities, natural mortalities were assumed to occur
at the mid-point of the six-month cycle, while fracture-
related excess mortalities were assumed to occur at the
start of the cycle.
Mortality risk has been found to increase after hip and
vertebral fractures [19,20,24]. Wrist and other types of
fractures were assumed not to affect mortality. These
multipliers are dependent on time since hip or vertebral
fractures: they were phased out over 6 years for vertebral
fractures and 7 years for hip fractures. If there were both
vertebral and hip fractures within the last 6 years, the
model used the larger risk multiplier.
Utilities
Health utility is known to be partly dependent on age
and gender. Base utilities used in the model were taken
from Swedish population norms found in Lundberg [21].
The reductions in health utilities after osteoporotic frac-
tures were based on Kanis [13], (Table thirty). A multi-
plier was used to calculate the utility weight after a
fracture, which implied that all fractures produce a per-
centage decline in health utility compared with the age-
specific average for healthy patients.
Health utility calculations in the model for all fractures
were based on the assumption that reductions in health
utility from fractures are multiplicative. If more than one
fracture occurred during the same six month cycle, the
health utility was estimated to be the product of the multi-
pliers for each fracture type and the base utility. Similarly,
the reduction in health utility for previous prevalent frac-
ture and the acute reduction in health utility for a new
fracture were multiplicative. For example, a clinical ver-
tebral fracture in a 60 year-old male with a previous
hip fracture would have a utility of 0.412 (calculated as
0.81[base] * 0.626[first-year vertebral] * 0.813[subsequent hip]) or
about a 49% reduction in health utility during the first
year after fracture.
For repeat occurrences of a particular type of fracture,
the model used the first-year utility multiplier in the year
of the repeat fracture and a specified proportion (25% by
default) of the disutility attributable to the subsequent
utility multiplier from the previous fracture. This pro-
duced results which were consistent with lower utilities
for multiple fractures of the same type identified in the
Lips [25] review of studies of quality of life in
osteoporosis.
Teriparatide efficacy
The efficacy of the intervention was measured as relative
risk reduction to fracture rates compared to no treat-
ment. For this model, these relative risk reductions were
based on clinical trials dealing with therapeutic interven-
tions reported in Neer [4], Lindsay [5], Prince [6], Genant
[7], and Kanis [13].
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Neer [4] and Genant [7] described the use of teripara-
tide versus placebo in the treatment of osteoporosis in
postmenopausal women. These efficacies were also used
as representative of the teriparatide efficacies in the
treatment of GIOP. The model incorporated the clinical
vertebral fracture relative risk results for teriparatide ver-
sus placebo (RR = 0.17) from Genant [7]. The model
incorporated the non-vertebral fracture (pooled hip,
wrist, ankle, humerous, rib, foot, pelvis and other) rela-
tive risk results for teriparatide versus placebo (RR =
0.47) from Neer [4]. These relative risks were held con-
stant for the 18 months of treatment.
The model used a 57% relative risk reduction (RR =
0.43) for clinical vertebral fractures compared to no treat-
ment for the 18-month period after discontinuation of
treatment with teriparatide. The risk reduction was based
on the sustained efficacy for the prevention of moderate
or severe vertebral fractures demonstrated by teriparatide
during an 18-month period after discontinuation of treat-
ment from Lindsay [5]. Mild vertebral fractures are usually
asymptomatic and therefore rarely receive clinical atten-
tion. As the model simulated only clinical vertebral frac-
tures, the risk reduction of moderate and severe vertebral
fractures in postmenopausal women was used as a proxy
for clinical vertebral fractures.
The model applied a 27% relative risk reduction (RR =
0.73) for hip and wrist fractures during the 30-month
period after discontinuation of teriparatide treatment
from Prince [6]. The results reported in Prince from the
Fracture Prevention Trial (FPT) were not powered to
isolate specific non vertebral fractures (e.g., hip frac-
tures), so a pooled RR reduction was applied to the
group. The fracture prevention efficacy of teriparatide
was modeled to decline linearly over an 18-month
period after the end of the sustained efficacy period.
Bisphosphonate efficacy
The model used a set of combined bisphosphonate anti-
fracture efficacies from the Kanis [13] study of GIOP
treatment. In that study, Kanis based those therapy effi-
cacies on two assumptions; (1) responses to intervention
did not differ between the bisphosphonates, and (2) frac-
ture risk reductions were similar for patients taking glu-
cocorticoids as for women with postmenopausal
osteoporosis. The current model implicitly used these
same assumptions.
The relative risks associated with bisphosphonate treat-
ment were held constant for the 18 month treatment
cycle. After completion of treatment, the relative risks
were ramped back to no benefit over an 18-month period.
This was based on the supposition that the treatment effi-
cacy of bisphosphonates is expected to decline to zero
during a period equal to the duration of treatment after
the discontinuation of treatment from Schousboe [26].
Currency conversions and base year
Conversions from Swedish currency to euros were per-
formed using the exchange rate of 9.0335 SEK per euro,
which was the average exchange rate over the previous
12 months ending December 2011 [16]. All non 2011
costs were inflated from their base year to January 2012
based on Sweden historical consumer price index (CPI)
values from Statistics Sweden [27].
Sensitivity analyses
One-way sensitivity analysis and probabilistic sensitivity
analysis (PSA) were performed for all cohorts. Only sen-
sitivity analyses for the 2-fracture cohorts were reported
in this manuscript.
For the one-way sensitivity analysis, individual model
input variables representing assumptions about treat-
ment efficacies, population fracture-related rates, epide-
miologic and demographic data, and economic variables
of interest were varied over specified ranges that
reflected uncertainties in their point estimates. Results
are displayed as tornado diagrams.
For the probabilistic sensitivity analysis, 1,000 simula-
tions of 1,000 patients were performed on each cohort.
For each simulation, the values of the critical parameters
were sampled from distributions. For this analysis, those
parameters were fracture treatment costs, fracture
related utilities, and drug efficacies in reducing fractures.
Scatter plots of incremental QALYs by incremental costs
and acceptability curves showing the probability that the
cost per QALY is less than various willingness-to-pay
thresholds are displayed for both 2-fracture cohorts.
For all of the specified distributions, the mean values
were set equal to the baseline estimate values. Fracture
costs were represented by lognormal distributions, while
the disutility due to fractures and fracture risk reduc-
tions due to treatment were represented by beta distri-
butions. Fracture costs were allowed to vary from 50%
to 200% of baseline. Fracture (dis)utilities were allowed
to range between the minimum and maximum disutility
values found in Schousboe [28] for each fracture type.
Fracture risk reductions due to treatment were allowed
to vary within the 95% confidence interval from the teri-
paratide clinical trials [4,7]. A detailed listing of the
probabilistic sensitivity analyses parameters is provided
in Additional file 1: Appendix A, Table A2.
The threshold for cost-effectiveness was set at €50,000
(451,675 SEK) throughout these results.
Results and discussion
Base case results
The major results for both the PMO and GIOP cohorts
evaluated are presented in Tables 2, 3, and 4. Clinical
fracture results estimated from the model are displayed
in Table 2. The results show fractures avoided per 1,000
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patients for teriparatide against no treatment and teri-
paratide against bisphosphonate. Each cohort evaluates
two cases: (1) patients with an historical and an incident
fracture and (2) patients with an incident fracture only.
Looking at Table 2, the results indicate a reduction
in fractures rate per 1,000 patients across both cohorts
with teriparatide use, which is consistent with its
expected efficacy over bisphosphonate. Depending on
the cohort and fracture history, these rates indicate
that teriparatide treatment would prevent between 245
to 433 fractures over no treatment and between 181
and 320 fractures over bisphosphonate treatment per
1,000 patients.
Table 3 presents the incremental undiscounted life
years associated with both cohorts. The data indicates
that the reduction of osteoporosis related fractures
improves the lifespan of both cohorts (by reducing frac-
ture related mortality). This benefit ranges from 102 to
153 additional life years per 1,000 patients for teripara-
tide against no treatment and 77 to 117 additional life
years per 1,000 patients for teriparatide against bispho-
sphonate treatment.
Table 4 presents the base case incremental cost ef-
fectiveness ratios for the cohorts evaluated. The model
estimates ICERs less than €50,000 per discounted
QALY in all cases. The ICERs estimated for the GIOP
cohorts are all smaller than those estimated for the
PMO cohorts with identical fracture profiles, even
though a T-score of −2.5 was evaluated against a T-score
of −3.0 for the PMO cohorts. This indicates that the
Table 2 Base case clinical results: fractures avoided per 1,000 patients
Cohort Evaluated Hip Fractures Vertebral Fractures Wrist Fractures
PMO Patients (100% Female), age 69 years, T-Score = −3.0
historical vertebral + incident vertebral fracture
Teriparatide vs. No Treatment 95 221 32
Teriparatide vs. bisphosphonate 66 166 27
incident vertebral fracture
Teriparatide vs. No Treatment 73 145 27
Teriparatide vs. bisphosphonate 51 108 22
GIOP Patients (80% Female), age 69 years, T-Score = −2.5
historical vertebral + incident vertebral fracture
Teriparatide vs. No Treatment 93 304 36
Teriparatide vs. bisphosphonate 63 227 30
incident vertebral fracture
Teriparatide vs. No Treatment 85 248 34
Teriparatide vs. bisphosphonate 57 184 28
Table 3 Base case clinical results: incremental life years per 1,000 patients
Cohort Evaluated Incremental Life Years
PMO Patients (100% Female), age 69 years, T-Score = −3.0
historical vertebral + incident vertebral fracture
Teriparatide vs. No Treatment 132
Teriparatide vs. bisphosphonate 102
incident vertebral fracture
Teriparatide vs. No Treatment 102
Teriparatide vs. bisphosphonate 77
GIOP Patients (80% Female), age 69 years, T-Score = −2.5
historical vertebral + incident vertebral fracture
Teriparatide vs. No Treatment 153
Teriparatide vs. bisphosphonate 117
incident vertebral fracture
Teriparatide vs. No Treatment 140
Teriparatide vs. bisphosphonate 106
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additional fracture risks associated with the GIOP cohort
were greater than the reduced fracture risks due to the
more favourable BMD score.
Detailed simulation results showing estimated frac-
tures, costs, QALYs, and life years for both cohorts are
presented in Additional file 2: Appendix B.
PMO Patients: one-way sensitivity analyses and PSA
results
Results from the one-way sensitivity analysis for the
PMO T-3.0/2 fracture cohort are displayed in Figure 2.
The specific values changed for the analyses are shown
in the figure. These results indicate that the variations
Table 4 Base case cost effectiveness results (with 95% CIs)
Cohort Evaluated Teriparatide vs. No Treatment Teriparatide vs. Bisphosphonate
PMO Patients (100% Female), age 69 years, T-Score = −3.0
historical vertebral + incident vertebral fracture €5,897 / QALY €19,371 / QALY
(€5,128 – €6,612) (€18,413 – €20,424)
incident vertebral fracture €18,701 / QALY €36,995 1 / QALY
(€17,612 – €20,062) (€35,252 – €38,944)
GIOP Patients (80% Female), age 69 years, T-Score = −2.5
historical vertebral + incident vertebral fracture €3,271 / QALY €15,155 / QALY
(€2,691 – €3,853) (€14,406 – €15,881)
incident vertebral fracture € 7,330/ QALY €20,826 / QALY
(€6,650 – €8,062) (€19,831 – €21,854)
Figure 2 One-Way Sensitivity Analysis Tornado Diagram: Teriparatide vs. Bisphosphonate ICERs for the PMO T −3.0/2 Fracture Cohort.
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made to every (single) major model parameter exam-
ined, except a linear teriparatide phase out period equal
to the duration of therapy, will generate Cost / QALY
estimates for teriparatide vs. bisphosphonate which are
less than the €50,000 per QALY threshold.
Figure 3 presents PSA results for teriparatide versus
treatment with bisphosphonate for the PMO cohort with
a historical and an incident vertebral fracture. The scat-
ter plot shows the mean incremental costs and QALYs
for 1,000 simulations, each with 1,000 patients. The
mean incremental cost and QALY for the base case
results for this cohort from Table 4 is also displayed, as
well as the €50,000 per QALY threshold.
From the 1,000 PSA simulations for the PMO −3.0, 2-
fracture cohort, 829 produced results with positive in-
cremental costs and positive incremental QALYs. 165
simulations estimated positive incremental QALYs for
teriparatide use versus bisphosphonate use with less in-
cremental costs (i.e., producing dominant results for
teriparatide); and 6 simulations estimated negative incre-
mental QALYs for teriparatide use with greater incre-
mental costs than bisphosphonate use (i.e., producing
dominant results for bisphosphonate use).
The acceptability curve for the PMO T-3.0/2 fracture
cohort is shown in Figure 4 for teriparatide against
bisphosphonate treatment. This curve was also based on
total incremental costs and QALYs from 1,000 simula-
tions of 1,000 patients. From the curve, it can be seen
that 74.3% of the simulations produced mean incremen-
tal costs per QALY less than €50,000.
GIOP patients: one-way sensitivity analyses and PSA
results
Results from the one-way sensitivity analysis for the
GIOP T-2.5/2 fracture cohort are displayed in Figure 5.
The specific values changed for the analyses are shown
in the figure. As with the PMO SA, the GIOP results in-
dicate that variations to (single) major model para-
meters, except a linear phase out of teriparatide efficacy
equal to the duration of therapy, will generate an ICER
for teriparatide over bisphosphonate use at less of
€50,000 per QALY.
Figure 6 presents PSA results for teriparatide versus
treatment with bisphosphonate in the GIOP cohort with
T-scores of −2.5 and a historical vertebral fracture and
incident vertebral fracture. From Figure 6, the incremen-
tal cost per QALY for teriparatide versus bisphosphonate
treatment was less than the €50,000 threshold in 79.9%
of 1,000 simulations for these GIOP patients.
Out of the 1,000 PSA simulations for the GIOP
T −2.5/2 fracture cohort, 810 produced results with
Figure 3 Scatter Plot of Incremental Costs and QALYs for PMO T −3.0/2 Fracture Cohort: Teriparatide vs. Bisphosphonate Treatment.
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positive incremental costs and positive incremental
QALYs. 188 simulations estimated positive incremental
QALYs for teriparatide use versus bisphosphonate use
with less incremental costs (i.e., producing dominant
results for teriparatide); and 2 simulations estimated
negative incremental QALYs for teriparatide use with
greater incremental costs than bisphosphonate use (i.e.,
producing dominant results for bisphosphonate use).
Figure 7 shows the acceptability curve for teriparatide
use versus bisphosphonate use with the GIOP T −2.5/2
fracture cohort. The acceptability curve was based on
the total incremental costs and QALYs from 1,000 simu-
lations of 1,000 patients. The acceptability curve was
determined by the cumulative percentage of simulations
that estimated a Cost per QALY less than a given value
for willingness to pay (WTP) on the X-axis.
Discussion
Our analysis looked at the first-line use of teriparatide against
bisphosphonates and no treatment for two significant high
risk osteoporosis cohorts. For both the PMO and GIOP
cohorts simulated, the base case results indicate that the use
of teriparatide as a first-line treatment is cost-effective at a
€50,000 per QALY ICER threshold. These results included
both teriparatide treatment versus no treatment and teripara-
tide treatment compared to bisphosphonate treatment.
One-way sensitivity analysis of the model suggests that
cost per QALY estimates for teriparatide versus bispho-
sphonate treatment will remain under the €50,000 thresh-
old through a wide variation of key parameters. The only
case where the €50,000 threshold was exceeded was where
the loss of teriparatide efficacy followed a linear decline
after treatment similar to bisphosphonate (equal to the
duration of therapy). That rate of post treatment efficacy
decline was substantially quicker than indicated by Lind-
say. Its use in this analysis is to highlight the importance
of post treatment efficacy offset and also to suggest an
area where further research may be warranted to extend
Lindsay’s results to longer post treatment time horizons.
Probabilistic sensitivity analyses results produced by
the model indicated that teriparatide was cost effective
at a €50,000 per QALY threshold in over 74% of the
replications simulated for both cohorts. From these
results, two particular observations stand out:
1. The percentage of simulations where the estimated
patients’ QALYs decreased with teriparatide usage
was 0.6% for the PMO T-3.0/2 fracture cohort and
0.2% for the GIOP T-2.5/2 fracture cohort. In these
cases, the mean QALY loss was less than - 0.03
QALYs for both cohorts.
2. For the PMO T-3.0/2 fracture cohort, the model
estimated a cost savings and improved patient
QALYs with teriparatide in 16.5% of the simulations.
For the GIOP T-2.5/2 fracture cohort, the model
estimated a cost savings and improved patient
QALYs in 18.8% of the simulations.
The PSA results from both cohorts suggest that (using
QALYs as a proxy) it is unlikely for teriparatide to have
Figure 4 Acceptability Curve for PMO T −3.0/2 Fracture Cohort: Teriparatide vs. Bisphosphonate Treatment.
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worse outcomes versus bisphosphonate for groups of
1000 patients, and if so the inferiority will be of small
magnitude. Consider the results in Figures 3 and 6 in
comparison to another treatment with identical mean
values for cost and QALYs, but with a wider range of
positive and (larger) negative QALYs. Without explicitly
understanding the causal relationships responsible for
those worst case (low QALY) scenarios, a decision
maker may be wise (as a matter of policy) to prefer
options that reduce estimated patient QALY risk.
The second observation relates to the PSA simulations
where both costs are reduced and QALYs improved with
teriparatide treatment versus bisphosphonate. These
results beg a further analysis: is there some cohort char-
acteristic or combination of characteristics (e.g., T-score,
gender, etc.) that has a statistically greater chance to gen-
erate these most favourable outcomes? Identification of
those characteristics (if they exist) might identify a pa-
tient sub group (or groups), which could lead to a more
selective use of both teriparatide and bisphosphonate
with lower costs per QALY for the entire cohort.
The strength of this model is the level of detail it
encompasses, particularly with respect to the generation
of fractures within the cohorts selected for analysis. The
model provides for significant flexibility to represent ini-
tial fractures, second fractures, and fracture related mor-
tality by patient age, BMD T-score, and gender. An
additional strength of the model is its ability to be con-
figured quickly for probabilistic and one way sensitivity
analysis. However, the level of data detail required for
this model also provides a drawback: data preparation,
meta-analysis, and verification for a new series of ana-
lysis are non-trivial.
A subtle point related to this analysis is that it uses a
given initial BMD T-score for all patients beginning
treatment. For both PMO cohorts, the T-score was −3.0.
In reality, a cohort of 69 year old PMO patients will have
a range of BMD T-scores worse than this minimum
entry point. The impact is that the cost effectiveness of
the most efficacious treatment (teriparatide) will be
underestimated as the number of fractures prevented
was estimated on a minimum condition.
Figure 5 One-Way Sensitivity Analysis Tornado Diagram: Teriparatide vs. Bisphosphonate ICERs for the GIOP T −2.5/2 Fracture Cohort.
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Previous cost effectiveness studies of teriparatide treat-
ment for PMO patients in Sweden have been published
by Lundkvist [14] and Borgström [29]. In the Lundkvist
study, a Monte Carlo simulation was used to model a
cohort of 69 year old PMO patients with a BMD T score
of −3.0. Two cohorts were evaluated, one with an his-
toric vertebral fracture and one with a recent vertebral
fracture and an historic vertebral fracture. The analysis
compared the cost effectiveness of an 18 month regimen
of teriparatide treatment against calcium and vitamin D
use (defined as no treatment).
The results presented by Lundkvist differ from those
presented here. Both Lundkvist and our results indicate
teriparatide treatment as a cost effective option versus
no treatment for similar PMO cohorts (at a €50,000 per
QALY threshold). Our estimates of ICERs, however, are
significantly more favourable to teriparatide. An initial
comparison of the models suggests that drug costs and
Figure 6 Scatter Plot of Incremental Costs and QALYs for GIOP T −2.5/2 Fracture Cohort: Teriparatide vs. Bisphosphonate Treatment.
Figure 7 Acceptability Curve for GIOP T −2.5/2 Fracture Cohort: Teriparatide vs. Bisphosphonate Treatment.
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post treatment efficacy (the phase out period of fracture
protection) are primarily responsible for these differ-
ences. Rerunning our model using the Lundkvist data
for these inputs on the PMO cohort with a T-score of
−3.0 and historical vertebral fracture, we estimated simi-
lar incremental costs (€4,547 vs. €5,219), QALYs (0.07
vs. 0.08), and ICERs (€64,644 vs. €64,144) to those
reported by Lundkvist. The results from the PMO co-
hort with T-score of −3.0 and historical and recent verte-
bral fracture were again similar between our model and
the Lundkvist model (e.g., ICERs were €19,091 and
€20,301 in the two models, respectively).
Borgström reports the cost effectiveness of teriparatide
against no treatment for a similar (but not identical)
Swedish PMO cohort to that evaluated here. Their ana-
lysis used a Markov model to estimate costs and outcomes
in 6 month cycles. Our review indicated differences in
treatment discontinuation and fracture related utilities
used by Borgström that would result in the lower ICER
for teriparatide versus no treatment reported in their base
case analysis. Regardless of these specific differences, how-
ever, both models indicate that teriparatide is cost effective
at a €50,000 per QALY threshold versus no treatment for
the similar PMO cohorts evaluated.
Subsequent to the work reported in this paper, Peasgood
[30] provided an extensive review of osteoporosis related
health state utilities. The fracture utility values used in our
model were all higher than the reference case multipliers
presented in Peasgood (Table 4) for similar fractures. The
impact is that QALY estimates (and hence the ICERs)
generated by our model were less favorable to treatments
that reduce fractures than a model using the Peasgood
reference case multipliers.
A limitation of this analysis is that teriparatide is com-
pared only to a basket of bisphosphonate treatments and
to no treatment; though other osteoporosis treatment
interventions are commonly prescribed. Additionally, in
order to analyse patient populations who potentially
would receive treatment with teriparatide, the PMO popu-
lations modeled were more severe than many patients
diagnosed with osteoporosis. The analyses only reflect pa-
tient populations with the specific characteristics modeled,
and thus do not reflect the actual demographic and epide-
miologic distribution in the PMO and GIOP populations.
A geographical observation is also important in inter-
preting these results: Sweden has a high incidence of
osteoporosis related fractures. While a direct translation
of these results with other Nordic countries may be rea-
sonably considered, some care should be applied in gen-
eralizing these results elsewhere.
Conclusions
The results from this study demonstrate that there are
high-risk osteoporosis patient cohorts where teriparatide
use as a first-line agent is a cost-effective treatment op-
tion compared to bisphosphonates or to no treatment.
These findings may provide useful information for clin-
ical decision making in the management of osteoporosis.
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